- This event has passed.
Presenter(s): Laurence Westreich, MD, Associate Clinical Professor of Psychiatry Division of Alcoholism and Drug Abuse, Department of Psychiatry, New York University School of Medicine
Michael Gendel, MD, Associate Clinical Professor of Psychiatry, University of Colorado, Denver Medical Director Emeritus, Colorado Physician Health Program
No CME provided for this archive.
This webinar will provide attendees with the most up-to-date information about the legal and procedural aspects of prescribing buprenorphine. Because of the extraordinary level of legal scrutiny buprenor phine prescribers face, they must be absolutely certain that their treatment protocols are clinically appropriate and stand up to the scrutiny of state investigators, DEA agents, and family members. Among other things, the webinar will address informed consent, specific DEA rules about buprenorphine, unusual or off-label treatment regiments, and the use of buprenorphine in the treatment of those with safety sensitive employment. The webinar will begin with a Question-and Answer format, and attendees from the live session will be able to submit particular questions to the speakers. The discussion will focus on the practical aspects of providing excellent clinical care while being aware and respectful of the extant laws, regulations, and protocols involved with prescribing this still-controversial medication.
- Recognize buprenorphine-specific Informed Consent themes
- Construct a coherent office policy for prescribing buprenorphine
- Collaborate with psychiatrists, therapists, and pain specialists
- Manage unusual buprenorphine regimens
- Minimize the risk of inappropriate prescribing and diversion
PC-based attendees Required: Windows® 8, 7, Vista, XP or 2003 Server
Mac®-based attendees Required: Mac OS® X 10